Marinus Pharmaceuticals | MRNS - Des Atouts



Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.44B 232M 2025-12
Eisai JPY 1.49T 48.22B 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
UCB EUR 18.16B 971M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12